Shefali Agarwal files SEC Form 4 disclosures for Epizyme, Inc.. They have made 3 open-market trades across 2 companies since 2019, most recently 2022-08-12.
CIK 0001746830
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FATE | SELL | 2022-06-07 | 2022-06-08 | $21.89 | $18K | -7.4% | +25.0% | +5.4% |
| FATE | SELL | 2022-06-03 | 2022-06-06 | $22.80 | $18K | -10.4% | +32.5% | +17.1% |
| EPZM | SELL · 10b5-1 | 2022-02-07 | 2022-02-09 | $1.50 | $2K | -9.8% | -21.4% | -65.7% |
| EPZM | SELL · 10b5-1 | 2022-02-02 | 2022-02-04 | $1.37 | $4K | +7.3% | -3.3% | -55.4% |
| EPZM | SELL · 10b5-1 | 2022-01-26 | 2022-01-28 | $2.02 | $6K | +63.2% | +40.6% | -36.6% |
| EPZM | SELL · 10b5-1 | 2021-12-06 | 2021-12-07 | $2.93 | $5K | -0.6% | -26.9% | -53.1% |
| EPZM | SELL · 10b5-1 | 2021-02-04 | 2021-02-05 | $11.21 | $11K | -4.0% | -19.3% | -38.8% |
| EPZM | SELL · 10b5-1 | 2021-01-25 | 2021-01-27 | $11.41 | $33K | -2.4% | -19.3% | -31.3% |
| EPZM | SELL · 10b5-1 | 2020-12-03 | 2020-12-07 | $13.54 | $34K | +4.9% | -4.0% | -26.2% |
| EPZM | SELL · 10b5-1 | 2020-06-26 | 2020-06-30 | $16.15 | $29K | -7.2% | -13.1% | -24.6% |
| EPZM | SELL · 10b5-1 | 2020-03-25 | 2020-03-26 | $15.28 | $19K | -11.1% | +3.2% | -2.7% |
| EPZM | SELL | 2020-01-24 | 2020-01-27 | $21.53 | $153K | +1.6% | +1.0% | -18.4% |
| EPZM | SELL · 10b5-1 | 2019-06-14 | 2019-06-17 | $11.97 | $14K | -2.4% | +0.6% | -2.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.